RxSight Reaches 300,000 Light Adjustable Lens Implant Milestone

Company celebrates landmark achievement and strong scientific presence at ASCRS 2026 conference.

Apr. 9, 2026 at 2:38am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph of an intraocular lens implant, revealing its intricate internal structure and highlighting the advanced technology that enables customized vision correction.An advanced intraocular lens implant technology that can be precisely adjusted after cataract surgery to optimize each patient's vision.Today in Tampa

RxSight, Inc. announced that over 300,000 of its Light Adjustable Lens (LAL) implants have been performed since launch, marking a significant milestone for the company's customizable vision correction technology. The company also highlighted its strong scientific presence at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) 2026 annual meeting, with 35 presentations showcasing the clinical evidence and versatility of the LAL system.

Why it matters

The LAL system is the first and only intraocular lens (IOL) technology that allows doctors to optimize a patient's vision after cataract surgery based on real-world feedback. This milestone demonstrates the growing adoption and impact of adjustable IOL technology, which is redefining the standard of care for cataract surgery by enabling personalized, high-quality vision correction.

The details

The 300,000 LAL implants performed represent a significant achievement for RxSight, highlighting the skill and dedication of the doctors who have leveraged this technology to deliver best-in-class clinical outcomes for patients. The presentations at ASCRS 2026 will cover a wide range of topics, from refractive accuracy to complex cases and evolving treatment strategies, showcasing the versatility and impact of the adjustable LAL system.

  • RxSight announced the 300,000 LAL implant milestone in advance of the ASCRS 2026 annual meeting.
  • The ASCRS 2026 annual meeting will take place in April 2026.

The players

RxSight, Inc.

An ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The company's Light Adjustable Lens system is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery.

Ron Kurtz, MD

President and Chief Executive Officer of RxSight.

Got photos? Submit your photos here. ›

What they’re saying

“The 300,000 milestone is a testament to the skill and dedication of the doctors who have leveraged LAL technology to deliver best-in-class clinical outcomes for patients and strong financial performance for their practices.”

— Ron Kurtz, MD, President and Chief Executive Officer of RxSight

What’s next

RxSight continues to expand access to the Light Adjustable Lens through its growing network of trained surgeons and certified practices across the United States and select international markets. The company remains focused on redefining what's possible in cataract surgery by delivering personalized vision with exceptional precision.

The takeaway

The rapid adoption of RxSight's Light Adjustable Lens technology highlights the growing demand for customizable vision correction solutions that can be optimized after cataract surgery. This milestone demonstrates the company's commitment to advancing the standard of care and empowering ophthalmologists to deliver personalized, high-quality vision to their patients.